Abstract:Camptothecin (CPT) is a potent anticancer agent for the treatment of colorectal cancer; however, it exhibits some limitations, including poor solubility, low stability, and low bioavailability via oral administration, which restrict its usability in clinical treatments. In addition, overproduction of reactive oxygen species (ROS) during chemotherapy induces drug resistance and severe intestinal side effects. In this study, silica-installed ROS scavenging nanoparticles (siRNP) with 50-60 nm in diameter were employed to overcome the aforementioned drawbacks of CPT. The solubility of CPT was significantly improved by incorporating it into the core of the nanoparticle, forming CPT-loaded siRNP (CPT@siRNP). The anticancer activity of CPT@siRNP against colorectal cancer cells (C-26) in vitro was significantly improved as compared to free CPT through higher efficiency of intracellular internalization and induction of apoptosis. Owing to its antioxidant properties, CPT@siRNP reduced cytotoxicity to normal endothelial cells, which was in sharp contrast to the high toxicity of free CPT. Oral administration of CPT and CPT@siRNP to the C-26 tumor-bearing mice exhibited antitumor activity, accompanied by effective suppression of tumor growth. Although CPT treatment suppressed tumor progression, it caused severe side effects, including intestinal damage and significant bodyweight loss. Interestingly, such noticeable side effects were not observed in the mice treated with CPT@siRNP, and the effect of tumor growth inhibition tended to be similar to or higher than that of CPT treatment. The results obtained in this study indicate that CPT@siRNP is a potential therapeutic nanomedicine for the treatment of colon cancer.Statement of significance Here we employed silica-containing antioxidant nanoparticle (siRNP) as promising oral delivery nanocarrier of campothecin (CPT) to treat colon cancer. The design of siRNP via covalent conjugation of antioxidant nitroxide radicals and the silanol groups in the polymer backbone contributes to a significant increase in the absorption of hydrophobic drug molecules inside the core and enhances the stability of nanoparticles in the gastrointestinal environment for oral drug delivery. CPT-loaded siRNP (CPT@siRNP) significantly improved solubility of CPT. As compared to free CTP, the CPT@siRNP treatment showed a significantly higher toxicity to colon cancer cell, inhibition of cancer cell migration, and induction of apopo-tosis. With the antioxidant feature, siRNP also significantly suppressed the intestinal side effects caused by CPT treatment in tumor-bearing mouse model.(c) 2022 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.

Redox Sensitive Lipid-Camptothecin Conjugate Encapsulated Solid Lipid Nanoparticles for Oral Delivery.

Core-crosslinked Nanomicelles Based on Crosslinkable Prodrug and Surfactants for Reduction Responsive Delivery of Camptothecin and Improved Anticancer Efficacy.

Redox-sensitive Dimeric Camptothecin Phosphatidylcholines-Based Liposomes for Improved Anticancer Efficacy

Dimeric camptothecin-loaded RGD-modified targeted cationic polypeptide-based micelles with high drug loading capacity and redox-responsive drug release capability.

Linear-like polypeptide-based micelle with pH-sensitive detachable PEG to deliver dimeric camptothecin for cancer therapy

Redox-responsive Amphiphilic Camptothecin Prodrug Nanoparticles for Targeted Liver Tumor Therapy.

Camptothecin Nanoprodrug Possessing Dual Responsiveness to Endolysosomal Ph and Cytosolic Redox for Amplified Cytotoxic Potency.

Redox responsive 7-ethyl-10-hydroxycamptothecin (SN38) lysophospholipid conjugate: synthesis, assembly and anticancer evaluation

CPT Loaded Nanoparticles Based on Beta-Cyclodextrin-grafted Poly(ethylene Glycol)/poly (L-Glutamic Acid) Diblock Copolymer and Their Inclusion Complexes with CPT

High Drug Loading, Reversible Disulfide Core-Cross-Linked Multifunctional Micelles for Triggered Release of Camptothecin

Poly(ethylene glycol) shell-sheddable nanomicelle prodrug of camptothecin with enhanced cellular uptake.

STUDIES ON CAMPTOTHECIN SOLID LIPID NANOPARTICLES

Mechanisms of Chitosan-Coated Poly(Lactic-Co-Glycolic Acid) Nanoparticles for Improving Oral Absorption of 7-Ethyl-10-hydroxycamptothecin

Preparation of a Camptothecin Prodrug with Glutathione-Responsive Disulfide Linker for Anticancer Drug Delivery.

A Silica-Based Antioxidant Nanoparticle for Oral Delivery of Camptothecin Which Reduces Intestinal Side Effects While Improving Drug Efficacy for Colon Cancer Treatment.

Camptothecin-based prodrug nanomedicines for cancer therapy

Prostate-Specific Membrane Antigen and Esterase Dual Responsive Camptothecin–Oligopeptide Self-Assembled Nanoparticles for Efficient Anticancer Drug Delivery

Engineering of peglayted camptothecin into core-shell nanomicelles for improving solubility, stability and combination delivery

A Polyphosphoester-Conjugated Camptothecin Prodrug with Disulfide Linkage for Potent Reduction-Triggered Drug Delivery

Dynamic Core Crosslinked Camptothecin Prodrug Micelles with Reduction Sensitivity and Boronic Acid-Mediated Enhanced Endocytosis: an Intelligent Tumor-Targeted Delivery Nanoplatform

Dual 7-Ethyl-10-hydroxycamptothecin Conjugated Phospholipid Prodrug Assembled Liposomes with in Vitro Anticancer Effects.